John Rex

John joined Advent in 2014. John’s career path to date has included broad industry experience as head of AstraZeneca’s antibiotic development group. In addition to the general work of pipeline building at AstraZeneca, a 4-year term as the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee gave John the opportunity to have extensive involvement with development of novel regulatory pathways for antimicrobial agents. Following the 2016 sale of the AstraZeneca development pipeline to Pfizer, John moved full-time to consulting.

In addition to his roles in two Advent portfolio companies (F2G and Macrolide), John is Chief Strategy Officer for CARB-X, an Expert-in-Residence at the Wellcome Trust, and a member of the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria.

John has an MD from Baylor College of Medicine and is board-certified in Internal Medicine and Infectious Diseases. Before moving to Industry in 2003, John was Professor of Medicine at UT Medical School-Houston with a focus on translational studies of novel antifungal agents and hospital epidemiology.

John is a Director and Chief Medical Officer of F2G Ltd and an advisor to Macrolide Inc.